Table 1 Baseline characteristics (n = 15)
From: Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema
Patient no. | Eye | DM, years | Lens status | Intravitreal injections | PRP (sessions) | Blood glucose (mg/dl) | Retinopathy status | IOP (mmHg) | BCVA Snellen (logMAR) | CRT (µm) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | L | 16 | NO1NC1 | 4 ranibizumab, 3 aflibercept | - | 179 | Moderate NP | 18 | 20/200 (1.00) | 415 |
2 | L | 18 | NO2NC2P2 | 1 bevacizumab, 3 aflibercept | - | 136 | Severe NP | 17 | 20/40 (0.30) | 514 |
3 | L | 15 | IOL | 5 aflibercept | - | 139 | Moderate NP | 16a | 20/150 (0.87) | 430 |
4 | R | 6 | IOL | 4 ranibizumab | 1 | 142 | Proliferative | 14a | CF 20 cm (1.90) | 1164 |
5 | L | 26 | IOL | 5 ranibizumab | 3 | 117 | Proliferative | 18 | 20/200 (1.00) | 838 |
6 | L | 27 | IOL | 3 ranibizumab, 2 aflibercept | 2 | 181 | Proliferative | 13a | CF 1.5 m (1.5) | 617 |
7 | R | 10 | IOL | 2 bevacizumab, 3 ranibizumab, 2 aflibercept | 2 | 86 | Proliferative | 18 | 20/50 (0.40) | 414 |
8 | L | 10 | IOL | 3 bevacizumab, 4 aflibercept | - | 142 | Mild NP | 15a | 20/50 (0.40) | 315 |
9 | R | 14 | NO2NC2 | 8 ranibizumab, 3 aflibercept | 2 | 110 | Proliferative | 12 | 20/200 (1.00) | 452 |
10 | R | 12 | IOL | 3 ranibizumab, 3 aflibercept | 3 | 118 | Proliferative | 14 | 20/200 (1.00) | 489 |
11 | R | 20 | NO1NC1 | 3 ranibizumab, 2 aflibercept | 3 | 119 | Proliferative | 14 | 20/80 (0.60) | 445 |
12 | L | 15 | NO1NC2 | 3 ranibizumab, 6 aflibercept | 4 | 165 | Proliferative | 14 | 20/200 (1.00) | 332 |
13 | L | 13 | IOL | 1 bevacizumab, 1 ranibizumab, 3 aflibercept | 1 | 108 | Proliferative | 15a | 20/50 (0.40) | 507 |
14 | L | 24 | NO2NC2 | 1 ranibizumab, 3 aflibercept | 3 | 200 | Proliferative | 18 | 20/150 (0.87) | 348 |
15 | L | 6 | IOL | 3 bevacizumab, 6 aflibercept | 4 | 150 | Proliferative | 15a | 20/60 (0.48) | 458 |